Skip to main content

Advertisement

SpringerLink
Log in

Are dietary and serum advanced glycation end-products related to inflammation and oxidation biomarkers in breast cancer patients: a follow-up study

  • Research
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

This study is aimed at evaluating the relationship between dietary and serum advanced glycation end-products (AGEs) with serum inflammatory and oxidative stress biomarkers in breast cancer (BC).

Methods

A sample of BC patients was followed for 12 months (March 2020–January 2022). Three-day food consumption record and serum samples were taken before surgery (T1), before chemotherapy (T2), at the 6th month of chemotherapy (T3), and at the 12th month of chemotherapy (T4). Dietary AGE intake was represented by carboxymethyl lysine (dCML). Serum levels of CML, inflammation, and oxidation biomarkers were determined with biochemical blood tests. The results were compared according to human epidermal growth factor receptor-2 (HER2) status.

Results

Thirty-two women with BC and 32 age and body mass index-matched healthy women participated. No significant correlation was found between dCML and serum CML, inflammatory or oxidative stress biomarkers at T1, T2, and T4. A weak positive correlation was demonstrated between dCML and serum malondialdehyde levels (rho=0.355, p=0.046) at T3. The serum CML, inflammation, and oxidation biomarker levels of the HER2− group were significantly higher than those of the HER2+ group at T1.

Conclusion

This study suggests that there is limited correlation between dCML and serum inflammation and oxidative stress biomarkers in BC patients. Inflammation and oxidative biomarker levels appear to decline with treatment although dietary and serum AGE levels show not a corresponding significant decline. The HER2− subtype appears to be associated with higher dietary and serum AGEs and higher inflammatory and oxidative stress biomarkers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Alimirzaie S, Bagherzadeh M, Akbari MR (2019) Liquid biopsy in breast cancer: a comprehensive review. Clin Genet 95:643–660. https://doi.org/10.1111/CGE.13514

    Article  CAS  PubMed  Google Scholar 

  2. Society AC (2017) Breast Cancer Facts & Figures 2017-2018

  3. Kamińska M, Ciszewski T, Łopacka-Szatan K et al (2015) Breast cancer risk factors. Menopause Rev 14:196–202. https://doi.org/10.5114/PM.2015.54346

    Article  Google Scholar 

  4. World Cancer Research Fund/American Institute for Cancer Research (2018) Continuous Update Project Expert Report 2018. Diet, nutrition, physical activity and breast cancer.

  5. Jia T, Liu Y, Fan Y et al (2022) Association of healthy diet and physical activity with breast cancer: lifestyle interventions and oncology education. Front Public Health 10:558. https://doi.org/10.3389/FPUBH.2022.797794

    Article  Google Scholar 

  6. Nowotny K, Schröter D, Schreiner M, Grune T (2018) Dietary advanced glycation end products and their relevance for human health. Ageing Res Rev 47:55–66. https://doi.org/10.1016/J.ARR.2018.06.005

    Article  CAS  PubMed  Google Scholar 

  7. Fishman SL, Sonmez H, Basman C et al (2018) The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med 24:59. https://doi.org/10.1186/s10020-018-0060-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Takeuchi M (2020) Toxic AGEs (TAGE) theory: a new concept for preventing the development of diseases related to lifestyle. Diabetol Metab Syndr 12:1–12. https://doi.org/10.1186/S13098-020-00614-3

    Article  Google Scholar 

  9. Omofuma OO, Turner DP, Peterson LL et al (2020) Dietary advanced glycation end-products (AGE) and risk of breast cancer in the prostate, lung, colorectal and ovarian cancer screening trial (PLCO). Cancer Prev Res (Phila) 13:601–610. https://doi.org/10.1158/1940-6207.CAPR-19-0457

    Article  CAS  PubMed  Google Scholar 

  10. Yu T, Zheng Y, Wang Y et al (2017) Advanced glycation end products interfere with gastric smooth muscle contractile marker expression via the AGE/RAGE/NF-kappaB pathway. Exp Mol Pathol 102:7–14. https://doi.org/10.1016/j.yexmp.2016.12.002

    Article  CAS  PubMed  Google Scholar 

  11. Dias JA, Fredrikson GN, Ericson U et al (2016) Low-grade inflammation, oxidative stress and risk of invasive post-menopausal breast cancer - a nested case-control study from the Malmö diet and cancer cohort. PLoS One 11:e0158959. https://doi.org/10.1371/journal.pone.0158959

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Tesařová P, Kalousová M, Jáchymová M et al (2009) Receptor for advanced glycation end products (RAGE)—soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Investig 25:720–725. https://doi.org/10.1080/07357900701560521

    Article  CAS  Google Scholar 

  13. Faul F, Erdfelder E, Lang A-G, Buchner A (2007) G* Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191. https://doi.org/10.3758/bf03193146

    Article  PubMed  Google Scholar 

  14. Erel O (2004) A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37:277–285. https://doi.org/10.1016/J.CLINBIOCHEM.2003.11.015

    Article  CAS  PubMed  Google Scholar 

  15. Erel O (2005) A new automated colorimetric method for measuring total oxidant status. Clin Biochem 38:1103–1111. https://doi.org/10.1016/J.CLINBIOCHEM.2005.08.008

    Article  CAS  PubMed  Google Scholar 

  16. Harma M, Harma M, Erel O (2003) Increased oxidative stress in patients with hydatidiform mole. Swiss Med Wkly 133:563–566

    CAS  PubMed  Google Scholar 

  17. Uribarri J, Woodruff S, Goodman S et al (2010) Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 110:911–916.e12. https://doi.org/10.1016/j.jada.2010.03.018

    Article  PubMed  PubMed Central  Google Scholar 

  18. Nutrition Data Base Software (2007) Data base: the German Food Code and Nutrient Data Base (BLS II.3, 1999) with additions from USDA-SR and other sources, Istanbul

  19. Lohman TG, Roche AF, Martorell R (1988) Anthropometric standardization reference manual. Human Kinetics Books, Champaign

    Google Scholar 

  20. WHO/Europe (2020) Nutrition - Body mass index - BMI

  21. IBM Corp. Released (2015) IBM SPSS Statistics for Windows, Version 23.0. IBM Corp, Armonk

    Google Scholar 

  22. Tan SY, Wong HY, Vardy JL (2021) Do cancer survivors change their diet after cancer diagnosis? Support Care Cancer 29:6921–6927. https://doi.org/10.1007/S00520-021-06276-9

    Article  PubMed  Google Scholar 

  23. Omofuma OO, Peterson LL, Turner DP et al (2021) Dietary advanced glycation end-products and mortality after breast cancer in the Women’s Health Initiative. Cancer Epidemiol Biomark Prev 30:2217–2226. https://doi.org/10.1158/1055-9965.EPI-21-0610

    Article  CAS  Google Scholar 

  24. Ahmad S, Khan H, Siddiqui Z et al (2018) AGEs, RAGEs and s-RAGE; friend or foe for cancer. Semin Cancer Biol 49:44–55. https://doi.org/10.1016/J.SEMCANCER.2017.07.001

    Article  CAS  PubMed  Google Scholar 

  25. Kwak T, Drews-Elger K, Ergonul A et al (2017) Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene 36:1559–1572. https://doi.org/10.1038/ONC.2016.324

    Article  CAS  PubMed  Google Scholar 

  26. Nankali M, Karimi J, Goodarzi MT et al (2016) Increased expression of the receptor for advanced glycation end-products (RAGE) is associated with advanced breast cancer stage. Oncol Res Treat 39:622–628. https://doi.org/10.1159/000449326

    Article  CAS  PubMed  Google Scholar 

  27. Zhang W, Deng X, Tang R, Wang H (2020) Receptor for advanced glycation end-product rs1800624 polymorphism contributes to increase breast cancer risk: Evidence from a meta-analysis. Medicine 99:e22775. https://doi.org/10.1097/MD.0000000000022775

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Xia W, Xu Y, Mao Q et al (2015) Association of RAGE polymorphisms and cancer risk: a meta-analysis of 27 studies. Med Oncol 32:442. https://doi.org/10.1007/S12032-014-0442-5

    Article  PubMed  Google Scholar 

  29. Pan S, Guan Y, Ma Y et al (2022) Advanced glycation end products correlate with breast cancer metastasis by activating RAGE/TLR4 signaling. BMJ Open Diabetes Res Care 10:e002697. https://doi.org/10.1136/BMJDRC-2021-002697

    Article  PubMed  PubMed Central  Google Scholar 

  30. Cairat M, Rinaldi S, Navionis A-S et al (2022) Circulating inflammatory biomarkers, adipokines and breast cancer risk—a case-control study nested within the EPIC cohort. BMC Med 20:118. https://doi.org/10.1186/s12916-022-02319-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kehm RD, McDonald JA, Fenton SE et al (2020) Inflammatory biomarkers and breast cancer risk: a systematic review of the evidence and future potential for intervention research. Int J Environ Res Public Health 17:1–21. https://doi.org/10.3390/ijerph17155445

    Article  CAS  Google Scholar 

  32. Mikkelsen MK, Lindblom NAF, Dyhl-Polk A et al (2022) Systematic review and meta-analysis of C-reactive protein as a biomarker in breast cancer. Crit Rev Clin Lab Sci. https://doi.org/10.1080/10408363.2022.2050886

  33. Khalaf MY, Mohammed AA, Mosa AA et al (2021) The correlation of antioxidant levels of breast cancer: a case-controlled study. Medicine 100:e26878. https://doi.org/10.1097/MD.0000000000026878

    Article  PubMed  PubMed Central  Google Scholar 

  34. Feng JF, Lu L, Zeng P et al (2012) Serum total oxidant/antioxidant status and trace element levels in breast cancer patients. Int J Clin Oncol 17:575–583. https://doi.org/10.1007/s10147-011-0327-y

    Article  CAS  PubMed  Google Scholar 

  35. Rockenbach G, di Pietro PF, Ambrosi C et al (2011) Dietary intake and oxidative stress in breast cancer: before and after treatments. Nutr Hosp 26:737–744. https://doi.org/10.1590/S0212-16112011000400011

    Article  CAS  PubMed  Google Scholar 

  36. di Pino A, Currenti W, Urbano F et al (2017) High intake of dietary advanced glycation end-products is associated with increased arterial stiffness and inflammation in subjects with type 2 diabetes. Nutr Metab Cardiovasc Dis 27:978–984. https://doi.org/10.1016/J.NUMECD.2017.06.014

    Article  PubMed  Google Scholar 

  37. Luévano-Contreras C, Garay-Sevilla ME, Wrobel K et al (2013) Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. J Clin Biochem Nutr 52:22–26. https://doi.org/10.3164/JCBN.12-40

    Article  PubMed  Google Scholar 

  38. Peterson LL, Park S, Park Y et al (2020) Dietary advanced glycation end products and the risk of postmenopausal breast cancer in the National Institutes of Health-AARP Diet and Health Study. Cancer 126:2648–2657. https://doi.org/10.1002/CNCR.32798

    Article  CAS  PubMed  Google Scholar 

  39. Uribarri J, Cai W, Peppa M et al (2007) Circulating glycotoxins and dietary advanced glycation endproducts: Two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 62:427–433. https://doi.org/10.1093/GERONA/62.4.427

    Article  PubMed  Google Scholar 

  40. Cepas V, Collino M, Mayo JC, Sainz RM (2020) Redox signaling and advanced glycation endproducts (AGEs) in diet-related diseases. Antioxidants 9:142. https://doi.org/10.3390/antiox9020142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Davis KE, Prasad C, Vijayagopal P et al (2016) Advanced glycation end products, inflammation, and chronic metabolic diseases: links in a chain? Crit Rev Food Sci Nutr 56:989–998. https://doi.org/10.1080/10408398.2012.744738

    Article  CAS  PubMed  Google Scholar 

  42. Garay-Sevilla ME, Beeri MS, de La Maza MP et al (2020) The potential role of dietary advanced glycation endproducts in the development of chronic non-infectious diseases: a narrative review. Nutr Res Rev 33:298–311. https://doi.org/10.1017/S0954422420000104

    Article  CAS  PubMed  Google Scholar 

  43. Erusalimsky JD (2021) The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes. Redox Biol 42:101958. https://doi.org/10.1016/J.REDOX.2021.101958

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Hirko KA, Willett WC, Hankinson SE et al (2016) Healthy dietary patterns and risk of breast cancer by molecular subtype. Breast Cancer Res Treat 155:579–588. https://doi.org/10.1007/S10549-016-3706-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Łukasiewicz S, Czeczelewski M, Forma A et al (2021) Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers 13:4287. https://doi.org/10.3390/cancers13174287

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Flores-García MK, Mérida-Ortega Á, Denova-Gutiérrez E et al (2021) Dietary patterns and breast cancer risk in women from Northern Mexico. Nutr Cancer 73:2763–2773. https://doi.org/10.1080/01635581.2020.1860241

    Article  CAS  PubMed  Google Scholar 

  47. Calaf GM, Ponce-Cusi R, Aguayo F et al (2020) Endocrine disruptors from the environment affecting breast cancer (review). Oncol Lett 20:19–32. https://doi.org/10.3892/OL.2020.11566

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Lee S, Quiambao AL, Lee J et al (2019) Dietary inflammatory index and risk of breast cancer based on hormone receptor status: a case-control study in Korea. Nutrients 11:1949. https://doi.org/10.3390/NU11081949

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Wang J, Xu B (2019) Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct Target Ther 4:1–22. https://doi.org/10.1038/s41392-019-0069-2

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank the women that have participated in this research. We would like to thank Turkish Society of Medical Oncology for supporting the research and Dr. Ahmad Qasim AL-KHATTAT for his valuable support in writing the manuscript.

Data availability

This manuscript is based on data of SBA’s PhD dissertation. The datasets of the current study are available from the corresponding author on reasonable request.

Funding

This research was supported by Turkish Society of Medical Oncology (Grant no. TTOD-2019-47).

Author information

Authors and Affiliations

  1. Department of Nutrition and Dietetics, Nezahat Keleşoğlu Faculty of Health Sciences, Necmettin Erbakan University, Konya, Turkey

    Şenay Burçin Alkan

  2. Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey

    Mehmet Artaç

  3. Department of General Surgery, Trabzon Kanuni Training and Research Hospital, University of Health Sciences, Trabzon, Turkey

    Faruk Aksoy

  4. Department of General Surgery, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey

    Mehmet Metin Belviranlı

  5. Department of Biochemistry, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey

    Mehmet Gürbilek

  6. Department of Internal Medicine, Necmettin Erbakan University, Konya, Turkey

    Hilal Akay Çizmecioğlu

  7. Department of Nutrition and Dietetics, Faculty of Health Sciences, Hacettepe University, Ankara, Turkey

    Neslişah Rakıcıoğlu

Authors
  1. Şenay Burçin Alkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehmet Artaç
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Faruk Aksoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehmet Metin Belviranlı
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mehmet Gürbilek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hilal Akay Çizmecioğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Neslişah Rakıcıoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SBA, MA, and NR designed the study. SBA, MA, FA, MMB, MG, and HCA were responsible for the clinical data extraction. SBA and NR wrote the first draft of the manuscript. MA and NR reviewed and revised the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Neslişah Rakıcıoğlu.

Ethics declarations

Ethics approval and consent to participate

Ethical approval for this study was obtained from the Ethics Committee of Necmettin Erbakan University, Konya, Turkey (2019/1866, 17 May 2019). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Consent for publication

Participants consented to having their data published.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alkan, Ş.B., Artaç, M., Aksoy, F. et al. Are dietary and serum advanced glycation end-products related to inflammation and oxidation biomarkers in breast cancer patients: a follow-up study. Support Care Cancer 31, 334 (2023). https://doi.org/10.1007/s00520-023-07772-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00520-023-07772-w

Keywords

Search

Navigation